As the 2023 Respiratory Syncytial Virus (RSV) season approaches the United States, a third vaccine may soon become available for older adults.
Moderna, Inc. today provided an update on regulatory submissions for mRNA-1345, a vaccine candidate for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older.
Read More
